Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Health insurance company Cigna (NYSE:CI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 11.1% year on year to $67.18 billion. Its non-GAAP profit of $7.20 per share was 0.6% above analysts’ consensus estimates.
Cigna Group (NYSE:CI) beat Q2 revenue estimates but slightly missed on EPS, reaffirming full-year guidance. Shares rose 4.4% pre-market as investors focused on growth.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Shares of health insurance company Cigna (NYSE:CI)
fell 3.1% in the afternoon session after the major indices pulled back (Nasdaq -0.8%, S&P 500 -0.77%), largely due to escalating concerns surrounding the July 9th deadline for new US tariffs, now amplified by specific announcements.
UnitedHealth, Centene, and Elevance suffered steep market cap losses amid earnings guidance withdrawals and potential Medicaid changes tied to new legislation.
Shares of managed care provider Centene Corp. (NYSE: CNC) dropped over 40% on Wednesday, marking the worst single-day performance in the company's history.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Cigna’s first-quarter results surpassed Wall Street’s revenue and non-GAAP profit expectations, with management highlighting strong performance from the company’s specialty pharmacy and pharmacy benefit services platforms. CEO David Cordani attributed momentum to the combined strengths of the EverNorth and Cigna Healthcare businesses, noting in particular the expansion of high-touch specialty services and broader adoption of biosimilar drugs. Cordani emphasized, “We delivered this performance in a dynamic environment with forces of change going beyond tariffs and trade, significant geopolitical, and evolving social impacts.” Management also pointed to disciplined capital deployment, including the completion of the Medicare business divestiture, as a contributor to the quarter’s results.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.
